SCHEMBL3361010

SCHEMBL3361010

COC(=O)C1C(COC(=O)OC(C)(C)C)C1(C)C

nearest known ligand 0.31

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
DGAT1 O75907 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3358613 0.85 POLA1 (0.32)
SCHEMBL1685671 0.81 PRKCA (0.31)
SCHEMBL3361471 0.80 POLA1 (0.31)
SCHEMBL1150190 0.78 LMNA (0.34)
SCHEMBL1149796 0.78 LMNA (0.32)
SCHEMBL2709838 0.76 PRKCA (0.30)
SCHEMBL3361579 0.76 POLA1 (0.34)
SCHEMBL1685638 0.76 NAAA (0.35)
SCHEMBL1685676 0.75 NAAA (0.33)
SCHEMBL3680328 0.74 LMNA (0.45)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1783111-B1 METHOD FOR PRODUCING OPTICALLY ACTIVE CYCLOPROPANECARBOXYLATE COMPOUND SUMITOMO CHEMICAL CO (JP) 2015-04-08 EP disclosed
US-7709651-B2 asymmetriccomplex of copper(I) trifluoromethanesulfonate and 1,1-bis[2-[(4S)-(tert-butyl)-oxazoline]]cyclopropane is added to 3-methyl-2-butenyl acetate and ethyl diazoacetate using dichloroethane solvent to effect reaction to produce ethyl 3,3-dimethyl-2-(acetoxymethyl)cyclopropanecarboxylate SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2010-05-04 US disclosed
US-7705165-B2 Method for producing optically active cyclopropanecarboxylate compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2010-04-27 US disclosed
US-7671210-B2 Process for production of optically active cyclopropanecarboxylate compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2010-03-02 US disclosed
EP-1783130-B1 METHOD FOR PRODUCING OPTICALLY ACTIVE CYCLOPROPANECARBOXYLATE COMPOUND SUMITOMO CHEMICAL CO (JP) 2009-12-30 EP disclosed
US-20090048450-A1 Process for production of optically active cyclopropanecarboxylate compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2009-02-19 US disclosed
US-20080027235-A1 Method for Producing Optically Active Cyclopropanecarboxylate Compound SUMITOMO CHEMICAL COMPANY, LIMITED 2008-01-31 US disclosed
EP-1783111-A1 METHOD FOR PRODUCING OPTICALLY ACTIVE CYCLOPROPANECARBOXYLATE COMPOUND Sumitomo Chemical Company, Limited (JP) 2007-05-09 EP disclosed
EP-1783130-A1 METHOD FOR PRODUCING OPTICALLY ACTIVE CYCLOPROPANECARBOXYLATE COMPOUND Sumitomo Chemical Company, Limited (JP) 2007-05-09 EP disclosed
US-20070032659-A1 Process for producing optically active cyclopropane compound and asymmetric copper complex for use in the same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2007-02-08 US disclosed
EP-1674445-A1 PROCESS FOR PRODUCING OPTICALLY ACTIVE CYCLOPROPANE COMPOUND AND ASYMMETRIC COPPER COMPLEX FOR USE IN THE SAME Sumitomo Chemical Company, Limited (JP) 2006-06-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080027235-A1 Method for Producing Optically Active Cyclopropanecarboxylate Compound ACSL6, AOC1, CA6 DGAT1 1087/4885
US-20090048450-A1 Process for production of optically active cyclopropanecarboxylate compound CBR3, C9, CBR1 DGAT1 1759/4885
US-20070032659-A1 Process for producing optically active cyclopropane compound and asymmetric copper complex for use in the same CBR3, AOC3, CBR1 DGAT1 1974/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.